India is home to more than 100 million diabetics, and the demand for anti-diabetic drugs is on the rise -- the Rs 20,611 crore anti-diabetic drug market in India is growing at 9 per cent or so.
Among the commonly used analgesic formulations (painkillers) found NSQ are combinations of paracetamol with ibuprofen, diclofenac and mefenamic acid. Medications using these combinations are commonly used to treat fever, mild migraine, period and muscle pain.
Indian pharmaceutical companies are stepping up their efforts to combat the problem of counterfeit drugs, employing a variety of strategies, from packaging innovations to engaging private investigation agencies. The stakes are high, as counterfeit medicines not only harm consumers but also tarnish the reputation of leading brands.
Which entrepreneur would willingly part with her or his hard-earned money for grasping, self-serving politicians? asks Debashis Basu.
Hospitals to recover from sluggish Q3; diagnostics' growth rate at pre-Covid levels.
Nutraceuticals, consisting of dietary supplements and functional foods with curative or nutritional benefits, are estimated to have a sales of $190 billion globally by 2010. India's food supplement and health food market is estimated currently at about $400 million. The country already has a clutch of established players focussing in this segment such as Avesthagen, Himalaya and Sami Labs.
The European Medicines Agency's review is the second setback to Alkem Laboratories
These brands belong to about 320 drugs of leading Indian pharmaceutical companies. The Drug Controller General of India's (DCGI's) office feels that these have been launched without its approval.
Sun Pharmaceuticals, Alkem Laboratories and Ochoa Laboratories have signed contracts with the Geneva-based Horphag Research.
The Rs 900-crore (Rs 9 billion) Alkem Laboratories and the leading US pharmaceutical and research company Oculus Innovative Sciences Inc are planning to set up a 50:50 joint venture in India
Torrent Pharmaceuticals' Rs 3,000 crore proposal for increasing FII investment limit to 35 per cent was the biggest in terms of value
A key lesson for the pharmaceutical sector in this case is to not downplay the significant impact that regulatory non-compliance can have on operations.
Indian companies are now more confident about the execution skills of local banks.
Financial shares were the top losers.
Unfavourable secondary market conditions aren't a big concern for IPOs by good quality companies.
The government must not enter into what will be a little more than a large-scale transfer of taxpayers' money to the operators of private hospitals.
The Delhi High Court on Friday stayed the ban on some fixed dose combination (FDC) drugs of Glaxo SmithKline, Wockhardt and Laboratories Griffon but said action against their sale could be taken in the absence of valid sale and marketing licence.
Top gainers from the Sensex pack are Infosys, Cipla, NTPC, ITC and Lupin
Capital goods shares continued to trade firm in late noon despite weak market trend on the back of encouraging core sector growth in February.
Metal shares were the top gainers with Hindalco up over 5%.
Heavy rains pummelled Mumbai and its suburbs in which two persons died of electrocution and bringing normal life to a grinding halt on Friday with several areas waterlogged.
A majority of India's billionaires gained wealth in the last one year in spite of the stock market decline.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances